Medicine, Human Health Technology Offers

Centre Technology Transfer CITTRU posted this:

New active compound for the prevention and treatment of infections caused by Zika virus (ZIKV)The subject of the offer is new active compound - sodium polystyrene sulfonate (PSSNa which can be used to prevent and treat infections caused by Zika virus (ZIKV).

Centre Technology Transfer CITTRU posted this:

Mouse model of primary biliary cholangitis and Method for selection of active compounds for treatment and/or prevention of primary biliary cholangitis The subject of the offer is mouse model of primary biliary cholangitis and method for selection of active compounds for treatment and/or prevention of primary biliary cholangitis.

Covid-19 Innovation Challenges by Innoget posted this:

A Novel Therapeutic Approach Targeting Coronavirus Replication-Essential RNAs by Oligonucleotides A Novel Therapeutic Approach Targeting Coronavirus Replication-Essential RNAs by Oligonucleotides. The research team plans to develop a drug to inhibit human SARS-CoV-2 replication. They will use comparative genomics to detect conserved regions within the coronavirus family, and within human CoV-19 population, in order to identify essential genes that can be targeted to inhibit the virus replication. Project ID : 47-2020-10912

Covid-19 Innovation Challenges by Innoget posted this:

The Use of Chip Scale Photonics for the Advanced, and Efficient Detection of Viruses The Use of Chip Scale Photonics for the Advanced, and Efficient Detection of Viruses Chip scale photonics technology is developing rapidly for diverse applications, from communication and computation to various types of sensing. The Levy group has pioneered diverse advanced chip scale photonic technologies, including for example low loss waveguides, high Q resonators, cutting edge filtering capabilities, integration of active and passive device on chip, and the manufacturing of hybrid chips bringing together microfluidics and photonic devices. Project ID : 47-2020-10886

Covid-19 Innovation Challenges by Innoget posted this:

Active Masks with Virus Neutralizing Properties Active Masks with Virus Neutralizing Properties Professors Willner and Pikarsky are developing masks and possible ventilation systems that will contain virus neutralizing properties. They have undertaken the development of matrices that neutralize pathogens which can be incorporated into fabrics, paper, or nonreactive particles such as silica or alumina. Project ID : 47-2020-10888

Covid-19 Innovation Challenges by Innoget posted this:

Relieving Lung disease in COVID-19 Patients with Aerosols that Carry Viral Genes Inhibitors Relieving Lung disease in COVID-19 Patients with Aerosols that Carry Viral Genes Inhibitors Step One: “Smart” micro - or nano-particles carrying inhibitors of the gene machinery in pathogens are developed. Step Two: In the presence of biomarkers, the inhibiting agents are released, leading to the localized destruction of the pathogens. Project ID : 47-2020-10887

Covid-19 Innovation Challenges by Innoget posted this:

5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs 5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs This study will test the hypothesis that treatment with a peptide comprising five units (5-MER), which is administered by injection or oral delivery, will substantially reduce chronic inflammation of the upper respiratory tract and lungs, thus ameliorating the effects of the Coronavirus disease. This will be achieved by targeting a major pro-inflammatory protein called SAA which plays an active role in the development of the disease. Furthermore, it is anticipated that the 5-MER peptide may also activate genes that provide resistance to chronic inflammation mediated by Coronavirus. Project ID : 47-2020-10890

Covid-19 Innovation Challenges by Innoget posted this:

Novel Activating Antibodies for Viral Treatment Novel Activating Antibodies for Viral Treatment Various pathogens (bacteria and viruses as well) bind to specific cell adhesion molecule in order to inhibit the immune response and/or to infect the host cells. However,upon binding and induction/activation, the cell adhesion molecule suppresses virus production by an SHP2-dependent process which involves also suppression of mTOR-mediated protein biosynthesis. Project ID : 47-2020-10898

Covid-19 Innovation Challenges by Innoget posted this:

Rapid Computational Screening of Natural Products for COVID-19 Anti-Viral Agents Some edible compounds are potent antiviral agents and were tested successfully against SARS and MERS viruses. They hence provide an large source for rapid development and production of cure against COVID-19. These compounds are commercially available, and are generally recognized as safe (GRAS), with a vast chemical diversity. Despite the high-level genetic similarity to other coronaviruses, such as SARS-CoV and MERS-CoV, recent works demonstrate major structural differences in SARS-CoV2 (the causal agent of COVID-19 disease) proteins. The need for specific anti-SARS-COV2 treatments is acute. Rapid screening of the food derived compounds, using chemoinformatic modeling tools that are common in our lab, allow the identification of a small number of potent antiviral candidate inhibitors of recent published SARS-CoV2 target proteins. Project ID : 47-2020-10884

Covid-19 Innovation Challenges by Innoget posted this:

Plant-based Diagnostic Kit to Detect Sick and Recovered SARS-CoV-2 Virus Patients Genetically modified plant systems that allow identification of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies Applications Preventing the spread of the epidemic Restoring economic activity by returning immune-positive, symptomless people to work Features System can be rapidly reproduced through seeds Essentially unlimited quantities, extremely inexpensive Can be used in any environment No need for special machinery Adaptable to other diseases Project ID : 47-2020-10883

Covid-19 Innovation Challenges by Innoget posted this:

Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19 Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19 We offer a fast and efficient diagnostic method which can be applied to a large amount of tests in a short time. Our method is based on a kit which identifies specifically the viral RNA biomarker. The test is characterized by reliability, sensitivity, rapid (not more than 10-15 minutes), low toxicity and reasonable cost. Project ID : 47-2020-10881

Covid-19 Innovation Challenges by Innoget posted this:

Systematic Computational Drug Repositioning to Treat COVID-19 Systematic Computational Drug Repositioning to Treat COVID-19 The genetic revolution which has taken place in recent years brings new opportunities to the field of drug discovery & repositioning. Using advanced comparative genomic, and data integration, our lab has been developing a state-of-the-art AI algorithm which maps drug and food supplements that are useful in treating diseases and improving health conditions. To create this algorithm, we have been integrating and analyzing massive amounts of genomic data from 1,600 genomes, 14 thousand compounds, 20,000 human genes, and a comprehensive database of phenotypic data. Project ID : 47-2020-10880

Covid-19 Innovation Challenges by Innoget posted this:

Screening of Drugs to Inhibit Viral Infections Our group has published a lot of work on the SARS Coronavirus. We were the first to characterize an important protein in the virus that has a very unusual structure and sequence (E protein). Moreover, this protein was unique to SARS and was not found in any other Coronavirus. Now importantly, the new 2019 Coronavirus has a very similar protein! Project ID : 47-2020-10879

Covid-19 Innovation Challenges by Innoget posted this:

A Unique Platform for Curing Coronavirus and Similar Lethal Diseases A Unique Platform for Curing Coronavirus and Similar Lethal Diseases A Unique Platform for Curing Coronavirus and Similar Lethal Diseases Project ID : 47-2020-10878

Covid-19 Innovation Challenges by Innoget posted this:

Fooling the Virus: A Fusion Protein as Virus-Specific Therapeutic Fooling the Virus: The Fusion protein as Virus-Specific Therapeutic An ACE2 A fusion protein of ACE2 with an Immunogenic Component Project ID : 47-2020-10877

Medicine, Human Health Technology Offers

Innovation Resources

Sitemaps

Support

Company

Top Posts Categories

Recognitions

Medicine, Human Health Technology Offers

Recognitions

Follow us